Dermabrasion combined with photodynamic therapy: a new option for the treatment of non-melanoma skin cancer

Yu, Nianzhou; Luo, Xi; Wei, Tianhong; Zhang, Qian; Yu, Jing; Wu, Lisha; Su, Juan; Chen, Mingliang; Huang, Kai; Li, Fangfang; Xie, Yang; Fang, Fang; Zhang, Liang; He, Renjie; Chen, Xiang; Bu, Wenbo

doi:10.1007/s10103-021-03381-3

Cited by 7 publications

(12 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Surgical excision is the current mainstay of treatment for NMSC [27]. Although it has some of the lowest recurrence rates recorded in the literature, patients are at risk for undesirable cosmetic outcomes, dis gurement, and dysfunction in the operative area [7,27]. As with other well-known treatment options such as cryosurgery and 5-Fluorouracil (5-FU), skin resurfacing procedures are an alternative to surgical treatment with promising evidence of e cacy demonstrated in the literature [5][6][7][8][9].…”

Section: Discussionmentioning

confidence: 99%

“…In addition to an absence of concrete guidelines for the treatment of NMSC with either skin resurfacing procedure, no insurer provided evidence from the literature supporting the requirement of ten or more lesions, leaving one to question the basis of this criterion [27,28]. Despite the quantity of lesions not being found to in uence the e cacy of treatment, insurance companies may have based this requirement on the high average number of lesions that are present in certain study populations [7,11,12]. Nonetheless, there are patients in these studies with less than ten lesions that had signi cant reductions or eradication of their cancer following these interventions [7,11,12].…”

Section: Discussionmentioning

confidence: 99%

“…Although it has some of the lowest recurrence rates recorded in the literature, patients are at risk for undesirable cosmetic outcomes, dis gurement, and dysfunction in the operative area [7,27]. As with other well-known treatment options such as cryosurgery and 5-Fluorouracil (5-FU), skin resurfacing procedures are an alternative to surgical treatment with promising evidence of e cacy demonstrated in the literature [5][6][7][8][9]. In addition to infrequent treatment requirements and a low overall cost of treatment, dermabrasion and chemical peels are set apart from the other nonsurgical methods by their ability to provide both eradication and prophylaxis against future lesions [6, 9, 27, 28].…”

Section: Discussionmentioning

confidence: 99%

“…Skin Resurfacing procedures, such as dermabrasion and chemical peels, have shown to be therapeutic for nonmelanoma skin cancers (NMSC), with clearance of precancerous or cancerous lesions demonstrated in up to 96% of patients [5][6][7][8][9][10][11][12]. These procedures may also play a large role in protection against the development of new precancerous lesions [5][6][7][9][10][11][12]. In patients suffering from chronic acne, studies have investigated resurfacing procedures as either monotherapy or complementary treatment to current acne regimens.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Insurance Coverage of Dermabrasion and Chemical Peel Procedures: A Critical Analysis of 58 American Insurance Companies

Finkelstein

Wieland

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: Dermabrasion and chemical peels are infrequently utilized methods of treatment for medical grade conditions despite demonstrations of favorable outcomes. This may be due to the discrepancy of insurance coverage for these procedures. Objective: To evaluate the frequency of insurance coverage for dermabrasion and chemical peel procedures in the treatment of acne, acne scarring, and non-melanoma skin cancers (NMSC). Methods and Materials: A cross-sectional analysis of 58 insurance companies by web-based search or phone interview determined the number of insurers with a publicly available policy on dermabrasion or chemical peels. For each policy, the coverage status and any corresponding criteria were extracted. Results: Dermabrasion to treat basal cell carcinoma and actinic keratosis was discussed by 13 (16%) and 21 (36%) insurers respectively. Twenty of twenty-three companies (87%) with a chemical peel policy for premalignant lesions provided coverage. Of the 25 companies (43%) that discussed treatment of acne with chemical peels, 14 (56%) provided reimbursement and 11 (44%) denied coverage. Coverage of acne was denied significantly less for chemical peels than for dermabrasion (p<0.006). Conclusion: Inconsistencies in both inclusion and coverage between insurance companies may create an artificial barrier to receiving care.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Insurance Coverage of Dermabrasion and Chemical Peel Procedures: A Critical Analysis of 58 American Insurance Companies

Finkelstein

Wieland

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…Surgical and non-surgical treatments such as topical therapies are mostly carried out for skin cancer lesions [ 51 ]. Depending on the cancer progression stage, skin cancers can be treated by surgery [ 52 ], immunotherapy [ 53 ], cryosurgery [ 54 ], laser therapy [ 55 ], curettage, desiccation [ 56 ], dermabrasion [ 57 ], targeted therapy, photodynamic therapy [ 58 ], chemotherapy and radiotherapy [ 59 ]. Commonly used medications against melanoma include 5-fluorouracil (5-FU, Efudex), Imiquimod, Resiquimod, Ingenol mebutate, Diclofenac, cisplatin, etc.…”

Section: Skin Cancermentioning

confidence: 99%

Gene Regulations upon Hydrogel-Mediated Drug Delivery Systems in Skin Cancers—An Overview

Mathiyalagan

Valappil

Yang

et al. 2022

Gels

View full text Add to dashboard Cite

The incidence of skin cancer has increased dramatically in recent years, particularly in Caucasian populations. Specifically, the metastatic melanoma is one of the most aggressive cancers and is responsible for more than 80% of skin cancer deaths around the globe. Though there are many treatment techniques, and drugs have been used to cure this belligerent skin cancer, the side effects and reduced bioavailability of drug in the targeted area makes it difficult to eradicate. In addition, cellular metabolic pathways are controlled by the skin cancer driver genes, and mutations in these genes promote tumor progression. Consequently, the MAPK (RAS–RAF–MEK–ERK pathway), WNT and PI3K signaling pathways are found to be important molecular regulators in melanoma development. Even though hydrogels have turned out to be a promising drug delivery system in skin cancer treatment, the regulations at the molecular level have not been reported. Thus, we aimed to decipher the molecular pathways of hydrogel drug delivery systems for skin cancer in this review. Special attention has been paid to the hydrogel systems that deliver drugs to regulate MAPK, PI3K–AKT–mTOR, JAK–STAT and cGAS-STING pathways. These signaling pathways can be molecular drivers of skin cancers and possible potential targets for the further research on treatment of skin cancers.

show abstract

Miniaturized all-in-one microneedle device for point of care light therapy

Zhao,

Wang,

Xiong

et al. 2024

npj Flex Electron

View full text Add to dashboard Cite

Light therapies have been applied to millions of patients for treating many kinds of diseases, especially superficial ones. Currently, mainstream light therapies utilize the combined effects of photosensitizers and light to either remove disordered tissue or promote the growth of healthy tissue. Adverse effects of light therapy, including metabolic burden caused by circulatory photosensitizer and skin damage induced by high irradiance light, are yet to be addressed. This study provides a Miniaturized all-in-one Light therapy Device (MiLD). All components required for light therapy, including dual-function microneedles, LED array, control circuit, and battery are integrated together to form a miniaturized portable device with 2 cm in length, 1.7 cm in width, 1.2 cm in height, and 3.6 g in weight. The all-in-one design and patch-to-cure operation of MiLD enables the successful demonstration of point-of-care light therapy. Satisfactory therapeutic effects have been verified in mice on both types of light therapy. Meanwhile, transdermally co-delivering both photosensitizer and light in situ fully avoids photosensitizer accumulation in blood and remarkably reduces the irradiance of light, therefore significantly alleviating metabolic burden and light-induced skin damage. Overall, the MiLD lays the technical foundation of point-of-care light therapy with its miniaturized all-in-one design, simple patch-to-cure operation, satisfactory therapeutic effects, and minimum adverse effects.

show abstract

Dermabrasion combined with photodynamic therapy: a new option for the treatment of non-melanoma skin cancer

Cited by 7 publications

References 26 publications

Insurance Coverage of Dermabrasion and Chemical Peel Procedures: A Critical Analysis of 58 American Insurance Companies

Insurance Coverage of Dermabrasion and Chemical Peel Procedures: A Critical Analysis of 58 American Insurance Companies

Gene Regulations upon Hydrogel-Mediated Drug Delivery Systems in Skin Cancers—An Overview

Miniaturized all-in-one microneedle device for point of care light therapy

Contact Info

Product

Resources

About